A Controlled Clinical Study to Evaluate the Safety and Efficacy of Qurs Tabasheer in the Management of Type 2 Diabetes Mellitus.

Patients diagnosed with diabetes mellitus attending the Outpatient Department of Majeedia Unani Hospital who are willing to participate will be screened according to predefined inclusion and exclusion criteria. Written informed consent will be obtained from each eligible participant prior to enrollment. After enrollment, patients will be randomized into two groups. Group A will receive the polyherbal formulation Qurs Tabasheer at a dose of 4.85 g daily, administered as three tablets twice daily, while Group B will receive Metformin 500 mg twice daily. Baseline demographic details, clinical examination findings, and relevant investigations will be recorded in the Case Report Form. Participants will be followed weekly for assessment of clinical signs and symptoms, with fasting blood sugar measured at each visit and documented in the Case Report Form. At the end of the 45 day treatment period, all baseline investigations including fasting blood sugar, postprandial blood sugar, complete blood count, liver function tests, kidney function tests, serum insulin, and lipid profile will be repeated and recorded in the Case Report Form. The primary outcome will be the change in fasting blood sugar from baseline to day 45, while secondary outcomes will include changes in postprandial blood sugar, serum insulin, lipid profile, and clinical symptom scores.